These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38704439)

  • 41. Janus Kinase Inhibitors Differentially Inhibit Specific Cytokine Signals in the Mesenteric Lymph Node Cells of Inflammatory Bowel Disease Patients.
    Hindmarch DC; Malashanka S; Shows DM; Clarke AS; Lord JD
    J Crohns Colitis; 2024 Apr; 18(4):628-637. PubMed ID: 37855324
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation.
    Wille K; Sadjadian P; Becker T; Kolatzki V; Horstmann A; Fuchs C; Griesshammer M
    Ann Hematol; 2019 Jan; 98(1):93-100. PubMed ID: 30155552
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The timing of venous thromboembolic events after spine surgery: a single-center experience with 6869 consecutive patients.
    Cloney MB; Hopkins B; Dhillon ES; Dahdaleh NS
    J Neurosurg Spine; 2018 Jan; 28(1):88-95. PubMed ID: 29125431
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Waiting for JAK inhibitor safety data.
    Kragstrup TW; Glintborg B; Svensson AL; McMaster C; Robinson PC; Deleuran B; Liew DF
    RMD Open; 2022 Feb; 8(1):. PubMed ID: 35197363
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study.
    Hoisnard L; Pina Vegas L; Dray-Spira R; Weill A; Zureik M; Sbidian E
    Ann Rheum Dis; 2023 Feb; 82(2):182-188. PubMed ID: 36198438
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Switching between JAK Inhibitors in Patients with Atopic Dermatitis: Unanswered Questions in Daily Clinical Practice.
    Mastraftsi S; Bakakis M; Tsiogka A; Afroditi Kleidona I; Gregoriou S
    Acta Dermatovenerol Croat; 2023 Dec; 31(3):162-164. PubMed ID: 38439732
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism.
    Carrier M; Le Gal G; Wells PS; Rodger MA
    Ann Intern Med; 2010 May; 152(9):578-89. PubMed ID: 20439576
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Understanding the efficacy of individual Janus kinase inhibitors in the treatment of ulcerative colitis for future positioning in inflammatory bowel disease treatment.
    Nakase H
    Immunol Med; 2023 Sep; 46(3):121-130. PubMed ID: 37036140
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study.
    Scheepers L; Yang Y; Chen YL; Jones G
    Semin Arthritis Rheum; 2024 Feb; 64():152314. PubMed ID: 38029717
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
    Robertson L; Yeoh SE; Ramli A
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011088. PubMed ID: 29244199
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk of Recurrent Venous Thromboembolism After an Initial Episode: Risk Stratification and Implications for Long-term Treatment.
    Agrawal V; Kim ESH
    Curr Cardiol Rep; 2019 Mar; 21(4):24. PubMed ID: 30828779
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Janus Kinase Inhibitors and Risk of Venous Thromboembolism: A Systematic Review and Meta-analysis.
    Bilal J; Riaz IB; Naqvi SAA; Bhattacharjee S; Obert MR; Sadiq M; Abd El Aziz MA; Nooman Y; Prokop LJ; Ge L; Murad MH; Bryce AH; McBane RD; Kwoh CK
    Mayo Clin Proc; 2021 Jul; 96(7):1861-1873. PubMed ID: 33840525
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Duration of anticoagulation following venous thromboembolism: a meta-analysis.
    Ost D; Tepper J; Mihara H; Lander O; Heinzer R; Fein A
    JAMA; 2005 Aug; 294(6):706-15. PubMed ID: 16091573
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Administrative codes inaccurately identify recurrent venous thromboembolism: The CVRN VTE study.
    Baumgartner C; Go AS; Fan D; Sung SH; Witt DM; Schmelzer JR; Williams MS; Yale SH; VanWormer JJ; Fang MC
    Thromb Res; 2020 May; 189():112-118. PubMed ID: 32199174
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Do women with venous thromboembolism bleed more than men during anticoagulation? Data from the real-life, prospective START-Register.
    Palareti G; Legnani C; Antonucci E; Cosmi B; Falanga A; Poli D; Mastroiacovo D; Pengo V; Ageno W; Testa S
    Ther Adv Drug Saf; 2021; 12():20420986211062965. PubMed ID: 34987749
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Timing of Prophylactic Anticoagulation and Its Effect on Thromboembolic Events After Surgery for Metastatic Tumors of the Spine.
    De la Garza Ramos R; Longo M; Gelfand Y; Echt M; Kinon MD; Yassari R
    Spine (Phila Pa 1976); 2019 Jun; 44(11):E650-E655. PubMed ID: 30475345
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk of venous thromboembolism in Korean patients with rheumatoid arthritis treated with Janus kinase inhibitors: A nationwide population-based study.
    Song YJ; Cho SK; Kim JY; You SH; Kim H; Jung SY; Sung YK
    Semin Arthritis Rheum; 2023 Aug; 61():152214. PubMed ID: 37172496
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The incidence and risk factors of recurrent venous thromboembolism during pregnancy.
    Galambosi PJ; Ulander VM; Kaaja RJ
    Thromb Res; 2014 Aug; 134(2):240-5. PubMed ID: 24835671
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients.
    Prandoni P; Noventa F; Ghirarduzzi A; Pengo V; Bernardi E; Pesavento R; Iotti M; Tormene D; Simioni P; Pagnan A
    Haematologica; 2007 Feb; 92(2):199-205. PubMed ID: 17296569
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors.
    Weitz JI; Szekanecz Z; Charles-Schoeman C; Vranic I; Sahin B; Paciga SA; Wang Z; Hyde C; Martin DA
    RMD Open; 2022 Nov; 8(2):. PubMed ID: 36323490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.